Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

SYDNEY (Reuters) - Australia's Sigma Healthcare shareholders approved in a vote on Wednesday a merger with Chemist Warehouse ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

“The experience was so powerful that we felt compelled to help support the legal development of psychedelic-assisted ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Eli Lilly has announced plans to acquire Scorpion Therapeutics ... as per a consensus forecast by GlobalData, the parent company of Pharmaceutical Technology. PI3K inhibitors are directed toward the ...

Sydney is jam-packed with gyms. From small studios to big mega-chains, single-service boutiques to multi-service offerings, and everything in between. The amount of choice can be overwhelming.

GlobalData is the parent company of Pharmaceutical Technology. Eli Lilly is focusing on expanding access to obesity treatments while leveraging new therapeutic indications and ensuring pricing ...

There’s nothing quite like dining out in the city. Whether for a first date, an anniversary, a family lunch, or any old Tuesday night—the Sydney/Eora CBD offers up a long list of delicious restaurants ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...